Novocure Inc — Federal Contractor Profile

Contractor Overview

Total Contract Value: $795,980 ($796.0K)

Total Awards: 14

Company Profile

NOVOCURE INC is a specialized medical technology company that focuses on the development and commercialization of innovative therapies for the treatment of cancer. The company's core capabilities include the design and implementation of its NovoTTF-100L medical device, which delivers non-invasive, targeted therapy to patients with recurrent glioblastoma. NOVOCURE INC has a limited number of government contracts, with a total value of $795,979.68 across 14 contracts, averaging $56,856 per contract. The company has not won any competitive contracts and has no sole-source contracts, indicating a reliance on non-competitive awards. The lack of recent contracts suggests a potentially stable or contracting business strategy. NOVOCURE INC's government business is relatively small and concentrated, with no specific agency clients mentioned. The company's track record and notable projects include the NovoTTF-100L therapy, which has been approved by the FDA and is used in clinical settings. The contract patterns reveal a focus on niche medical technology solutions, and the company's market position is that of a specialist in targeted cancer therapies. NOVOCURE INC provides good value for taxpayer money, given the specialized nature of its services and the potential for significant patient benefit. However, the lack of competitive awards and the concentration of business may pose risks to the government's dependency on the company.

Specializations

• Cancer treatment
• NovoTTF-100L medical device
• Targeted therapy
• Glioblastoma treatment

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0%

Agency Concentration: moderate

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: 100%

Competitive Position

NOVOCURE INC is a niche specialist in the field of targeted cancer therapies, particularly for glioblastoma. The company holds a unique position in the market with its NovoTTF-100L device, which is not widely available or used. This specialization allows the company to maintain a strong market position, but the lack of competitive awards suggests that the company may face challenges in expanding its business through competitive bidding.

Value to Taxpayers

NOVOCURE INC provides good value for taxpayer money, especially given the specialized nature of its services. The NovoTTF-100L therapy has been approved by the FDA and is used in clinical settings, indicating its potential for significant patient benefit. However, the company's limited government business and lack of competitive awards may indicate that it is not actively seeking to expand its market share through competitive bidding, which could limit its ability to provide cost-effective solutions.

Agency Relationships

NOVOCURE INC has a moderate concentration of government clients, with no specific agencies mentioned. The company's limited business with government agencies suggests that it may not have a strong dependency on any single agency. However, the lack of recent contracts and the absence of competitive awards may indicate that the company is not actively seeking to expand its government business.

Red Flags

• No recent contracts: This suggests that the company may be facing challenges in securing new government business.
• No competitive awards: The company has not won any competitive contracts, which may indicate a lack of competitive advantage in the market.
• Limited government business: The company's limited government business may pose risks to the government's dependency on the company.

Green Flags

• Specialized medical technology: NOVOCURE INC's focus on specialized medical technology, particularly the NovoTTF-100L device, provides a unique market position.
• FDA approval: The NovoTTF-100L therapy has been approved by the FDA, indicating its potential for significant patient benefit.
• Diverse portfolio: The company's portfolio includes both government and commercial clients, which may provide a more stable revenue stream.

Key Contracts

NOVOCURE INC has a limited number of government contracts, with a total value of $795,979.68 across 14 contracts, averaging $56,856 per contract. The company's most significant contract is likely related to the NovoTTF-100L therapy, which has been approved by the FDA and is used in clinical settings. This contract reveals the company's capabilities in developing and commercializing innovative cancer therapies. The company's track record and performance history suggest that it is capable of delivering high-quality medical solutions. However, the lack of recent contracts and the absence of competitive awards may indicate that the company is not actively seeking to expand its government business. This could pose risks to the government's dependency on the company, as the company may not be able to provide cost-effective solutions or maintain its market position in the long term.

Frequently Asked Questions

Recent Federal Contracts

Novocure Inc has 7 federal contracts on record. Below are the largest awards:

Related Pages